Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From 10Q
On October 15, 2019, we entered into an agreement with CLSA Capital Markets Limited, a CITIC Securities Company, to provide introductions to potential strategic partners and regulatory guidance to support the launch of our proprietary genetic-based products into China’s (PRC) rapidly growing markets for women’s health and fertility. We anticipate introducing ARTguide™ among other fertility diagnostics to the Chinese market. In 2016 the National Health and Family Planning Commission of the PRC reported that 40 million Chinese couples were experiencing fertility issues. Similarly, the American Society for Reproductive Medicine (ASRM) reported in 2017 that an estimated 25% of Chinese women of childbearing age struggled with infertility issues. In 2018 the European Society of Human Reproduction and Embryology estimated that approximately 800,000 assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF), were being performed in China annually. Chinese women are driving the fertility markets both in China and medical tourism industries overseas. The global IVF market is expected to grow at an annual rate of 10.2% and to reach $36.2 billion by 2026. The U.S. Center for Disease Control reported that of the patients who sought fertility care in 2017, 284,385 ART cycles were performed resulting in 78,052 live born infants with ART accounting for 1.7% of all infants born in the U.S. annually.
Chinese market is huge!
Hopefully it will cut a lot of time and cost from the process
351 path and 361 paths are quite different in time frames and costs. If it is 351 path, best to exit and concentrate on core business and not stem cells.
Lack of quarter to quarter stem cell revenue growth is reflected in the current stock price.
Does that somebody include you, SG?
Thomas, by saying 74M women diagnosed, you mean that is an estimate based upon a sample of the population, correct? Otherwise that's a lot of surgeries!
Thanks for the post and I figured they wanted you to tone it down!
All I know is a year from now, people that know about the company today will be whining and saying why didn't I buy (more) PRED under $1????
Have to believe that there is quite a bit of tax loss selling for people that bot 3+
Obviously No One Cares
Then we will finally have a good bottom!!
Yes I'm sure they have a plan and my cost basis is below this price level. It's just the lack of information doesn't inspire confidence for potential new investors.
Totally agree. No meat to the PRs like how they are going to sell the kits/tests. It doesn't attract new investors. Only is beneficial to people that have already done their DD (preaching to the choir).
And of course it will never happen. It makes no sense for anyone to pump millions into a POS company that only has very little revenue and loses money that will reinvest the money to buy convertibles of its own stocks and other loser stocks.
The question is : are they going to keep stem cells for FDA approved treatments? For example the recently announced trial for knee pain/OA. Thoughts?
Thanks great update. You have no clue what those papers contain.
Also, why are the PRs so vague? Are they trying to hold down the share price for some reason? For example, how are they going to sell and distribute ArtGuide? Hire a direct sales force, through a partner, or some other way?
Thanks Thomas. Unfortunately I don't speak biology so I'm sending them to someone that might understand them!!
Let's put things in perspective. The poop test company (only one product on market) EXAS has a market cap and enterprise value north of $12B (well off it's 52 week highs). Their projected sales for 2019 are $812M. Their TTM sales are $623M. That means their current stock price is 20 times TTM sales. BTW they are losing money every year. Their EBITDA for TTM is negative $124M.
If PRED can do $300M in sales in 2020, it's stock price could be $20 per share if using the same multiple times sales. Would you be happy with that price at this point? I would!
You've got it.
He said this at the bottom ...
"We are holding and will take some of our equity off the table at $25 to $30 per share and we have substantially more shares than most on this blog."
Seems the same to me but yes I do know there is a difference.
As I stated before its because the PRs did not have enough substance to them. We need something with meat on it to raise the stock price and get on NASDAQ. Haven't seen it yet. And yes I am still long but disappointed in lack of upward movement. Perhaps we should adjust Thomas' end of year forecast to 2.50 to 3.00 (from 25 to 30).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151744849
That would be nice for a change!
I really don't know why people are wondering why the stock price isn't going up. The last three PRs look like complete puff pieces and lack any significant or material details.
So how are they going to sell ARTGuide? Direct sales or through a partner or both?
Fertility RX is going to be sold for $0 to select clinics. That will last for at least 6 months.
The most recent PR with the Chinese bank is totally vague. Unless you are in the know, you don't have a clue what that is really all about.
The question is: How is PRED going to attract new investors. Most investors want it spelled out for them and don't want to try to read between the lines. Until something more obvious and impactful is announced, the stock price isn't going to move up much.
JMHO
Snakes any idea when the results of the study they started in Sept will come back?
Looks like trial based for Fertility DX
Still a stock where most people never heard of.
Missing is how they are going to sell it.
8k Item 4.01 Changes in Registrant’s Certifying Accountant
On October 7, 2019, the Company’s Board of Directors elected to retain Deloitte & Touche LLP (”Deloitte”) as its independent registered public accounting firm in place of BF Borgers CPA PC (“Borgers”). The decision to change independent registered public accounting firms was recommended by the Company’s Audit Committee and approved by its Board of Directors.
The reports of Borgers on the June 30, 2019 and 2018 financial statements of the Company, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the Company’s two most recent fiscal years and all subsequent interim periods preceding such change in auditors, there was no disagreement with Borgers on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of the former accountant, would have caused it to make a reference to the subject matter of the disagreements in connection with its report; nor has Borgers ever presented a written report, or otherwise communicated in writing to the Company or its board of directors the existence of any “disagreement” or “reportable event” within the meaning of Item 304 of Regulation S-B.
The Company has authorized Borgers to respond fully to the inquiries of Deloitte, and Borgers has provided the Company with a letter addressed to the SEC, as required by Item 304(a)(3) of Regulation S-B, that is attached hereto as Exhibit 16.1.
It's because of Cost of sales on free test kit evaluations.
No effect on tomorrow's open (by itself).
Reported $48K Revenue for Diagnostics & Therapeutics (page 51). Possibly starting to charge for the test kits. They have been giving them away over the past year.
Top page 36 - During the twelve months ending June 30, 2019 we launched two new molecular diagnostic tests. PGxPLUS+ was launched in the 2nd quarter with consecutive quarter over quarter volume growth. The PGxPLUS+ test is currently being used to help physicians assess medication selection for patients with chronic pain. In the fourth quarter we grew our pharmacogenomic test volume (PGxPLUS+) 86% compared to the previous quarter. In the third quarter, we signed an agreement with Houston Fertility Institute (HFI) to continue the clinical evidence development of the ARTguide genetic test for Reproductive Endocrinologists. A priority of the agreement will be to establish clinical utility data demonstrating improved outcomes from the utilization of ARTguide for patients receiving fertility treatment. In the fourth quarter we increased ARTguide test volume 25% compared to the preceding quarter.
TL so what is wrong? Aside from the recent price action?
Because the insiders (management) doesn't care about the day to day movements of the stock.
Revenue and net profit up 4% from last quarter
They don't usually do Friday PRs. Isn't it usually Tuesday or Thursday?
He can't tell you if he knows about such deal. It's inside info.
The IR people are worthless anyway. You didn't miss anything.
I don't expect anything immediately out of the board meeting. The meetings are for the board to give direction to management and decide M&A activities. Expecting news this week is expecting too much. Neither Warren Buffett or Jimmy Buffett will be named to the board either.
Yea it's a lot of injuries for a quarterback. Results of not great protection that QBs like Tom Brady have had.
He's very smart (Stanford grad). He's got a bright future ahead of him. Like Gronk, get out before you have lifetime lasting injuries.
I don't hate him at all. I find him very amusing actually. Just having some fun.